

# MELANOMA: Updates from Brisbane, Australia



## References

- Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced  $BRAF^{V600}$ -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2016;17:1248-1260.
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *New Engl J Med.* 2012;366:2455-2465.
- Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. *RMD Open.* 2017;3:e000412.
- Gibney GT, Kudchadkar RR, DeConti RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. *Clin Cancer Res.* 2015;21:712-720.
- Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol.* 2016;17:1558-1568.
- Johnson DB, Pectasides E, Feld E, et al. Sequencing treatment in BRAFV600 mutant melanoma: Anti-PD-1 before and after BRAF inhibition. *J Immunother.* 2017;40:31-35.
- Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *New Engl J Med.* 2014;371:1877-1888.
- Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic  $BRAF^{V600E/K}$ -mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol.* 2017;28:1631-1639.
- Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer.* 2016;54:139-148.
- Puzanov I, Ribas A, Daud A, et al. Pembrolizumab for advanced melanoma: Effect of  $BRAF^{V600}$  mutation status and prior BRAF inhibitor therapy. 12th International Congress of the Society for Melanoma Research. San Francisco, November 21, 2015.
- Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol.* 2015;16.
- Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA.* 2016;315.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *New Engl J Med.* 2015;372:2521-2532.

# MELANOMA: Updates from Brisbane, Australia



Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *New Engl J Med.* 2015;372:30-39.

Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol.* 2010;28:3042-3047.

Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet.* 2017;390:1853-1862.

Simeone E, Grimaldi AM, Festino L, et al. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. *Oncoimmunology.* 2017;6:e1283462.

Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. *Cancer.* 2011;117:4740-4746.

Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New Engl J Med.* 2012;366:707-714.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New Engl J Med.* 2012;366:2443-2454.

Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *New Engl J Med.* 2017;377:1824-1835.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *New Engl J Med.* 2017;377:1345-1356.